Search
CTCE-0214
go.drugbank.com/drugs/DB05934ExperimentalCTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood
VP025
go.drugbank.com/drugs/DB05133ExperimentalVP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.
Dodecyltrimethylammonium
go.drugbank.com/drugs/DB02779ExperimentalSynonyms: N,N,N-Trimethyl-1-dodecanaminium, n-DodecyltrimethylammoniumCategories: Compounds used in a research, industrial, or household settingCalcium oxide
go.drugbank.com/drugs/DB15648InvestigationalCategories: Compounds used in a research, industrial, or household settingFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
4-nitrophenyl-beta-D-galactoside
go.drugbank.com/drugs/DB02632ExperimentalCategories: Compounds used in a research, industrial, or household settingL523S
go.drugbank.com/drugs/DB06498InvestigationalAccording to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)."
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).
NCX 1022
go.drugbank.com/drugs/DB05410ExperimentalNCX is an NO-releasing derivative of hydrocortisone.
Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16923ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.